p53 is one of the most important tumor suppressor genes in human cancer, but the roles of its homologues p63 and p73 in tumor suppression, alone or in collaboration with p53, remains controversial. Both p63 and p73 can be deregulated after DNA damage, and induce cell cycle arrest and apoptosis, but mice carrying inactive alleles of these genes do not develop spontaneous tumors. Since heterozygous loss of p53 confers strong sensitization to radiation-induced lymphoma development, we investigated the possibility that radiation exposure may reveal previously undetected tumor suppressor properties in p63 or p73, alone or in combination with p53. Animals heterozygous for p63 or p73, as well as both double heterozygous p53/p63 or p53/p73 mice, showed no significant differences in tumor latency, spectrum or frequency after gamma-radiation, compared to their control counterparts. Deletions were found near the p63 locus on chromosome 16 in radiation-induced tumors, but these frequently included the knockout allele. No deletions or LOH involving the p73 gene were detected, and expression of both genes was maintained in the tumors. We conclude that p53 homologues do not contribute to p53 tumor suppressor activity in lymphoma development. Oncogene (2005 Oncogene ( ) 24, 5521-5524. doi:10.1038 published online 20 June 2005 Keywords: p53; p63; p73; tumor suppressor; radiation; lymphoma Cancer is the consequence of multiple genetic alterations that lead to a selective growth advantage in tumor cells. The most frequently mutated gene in human cancers is p53 (Olivier et al., 2002) , which is a key component of the DNA damage response. p53 family members, p63 and p73, have remarkable structural similarities with p53, but their roles in cancer development are still controversial. Both p63 and p73 proteins, when overexpressed, can transactivate p53-response genes, and induce growth arrest and apoptosis in a p53-like manner (Jost et al., 1997; Yang et al., 1998; Agami et al., 1999; Gong et al., 1999; Yuan et al., 1999; Dohn et al., 2001) . On the other hand, p63 and p73, like p53, are deregulated after DNA damage (Gong et al., 1999; Liefer et al., 2000) or oncogene overexpression leading to apoptosis (Zaika et al., 1999) . However, in contrast to p53, viral oncoproteins that bind and inactivate p53 during cell transformation do not interact with either p63 or p73 (Marin et al., 1998) , and p63/p73 are not inactivated by point mutations in a large series of cancers . Moreover, p63/p73 knockouts show specific developmental defects but no spontaneous tumors (Mills et al., 1999; Yang et al., 1999 Yang et al., , 2000 .
We previously demonstrated that, the p53 gene protects mice from the tumorigenic effect of radiation exposure. A single dose of 4 Gy radiation induces mainly lymphoma development and decreases the average lifespan of p53 heterozygous knockout mice by about 35 weeks, without affecting the lifespan of control wildtype animals (Kemp et al., 1994) . The fact that p63 and p73 can be induced after DNA damage by gamma radiation or ultraviolet light (Gong et al., 1999; Liefer et al., 2000) suggests that their deficiency might lead to tumor development after gamma radiation. In order to determine whether p53 homologues confer protection against tumor development after radiation exposure, groups of p63 and p73 heterozygous mice received a single dose of 4 Gy whole body gamma-irradiation at the age of 5 weeks. Wild-type mice from the same litters were used as controls in order to eliminate any possible genetic background effects. After radiation, all of the mice were monitored daily for tumor development. Surprisingly, neither p63 nor p73 heterozygous mice developed significantly more tumors than their control counterparts ( Figure 1 ). Only a small number of mice developed tumors after 1 year, but there were no significant differences between p63 or p73 heterozygous and wild-type mice with respect to tumor development (P-value ¼ 0.78 and 0.89, respectively).
These results confirmed that loss of one allele of p63 or p73 does not confer increased tumor susceptibility even after radiation exposure. It has previously been shown, at least in mouse embryonic fibroblasts, that p53-induced apoptosis requires the participation of the p63 and p73 family members (Flores et al., 2002) . However, a recent study indicated that, at least in thymocytes, p53-dependent apoptosis occurs independently of p63 and p73 (Senoo et al., 2004) . In order to determine whether p63/p73 deficiency collaborates with loss of p53 in thymic lymphoma development, single p53, and double p53/p63 and p53/p73 heterozygous mice received a single dose of 4 Gy gamma radiation. The mice were monitored daily for tumor development. Again, there were no significant differences in tumor latency, frequency ( Figure 2 ) and spectrum (Table 1) between p53 single and p53/p63 or p53/p73 double heterozygous mice. These results suggest that p63 or p73 deficiency does not confer any growth advantage in the context of p53 deficiency. Since almost all tumors in p53 heterozygous mice lose the remaining functional p53 allele, we asked whether similar genetic events might lead to loss of p63 or p73 in tumors from the single or double heterozygous mice. Initially, we investigated the possible occurrence of p63 and p73 deletions by microsatellite analysis in lymphomas from double p53/ p63 and p53/p73 heterozygous mice. Whereas loss of the p53 wild-type allele was detected in 100% of tumors (Figure 3a) , the wild-type p73 allele was not lost in any of the tumors (Figure 3b ). The gene encoding p63 is located on chromosome 16, and loss of heterozygosity (LOH) in this region of chromosome 16 has been previously reported in radiation-induced lymphomas (Cai et al., 2002; Mao et al., 2004) . In agreement with these early results, the p63 locus was frequently deleted in tumors from single p53 and double p53/p73 heterozygous mice (60 and 80%, respectively); in the case of double p53/p63 double heterozygous mice it was also deleted in 70% of the cases. In the latter case, however, the deletion involved the knockout allele in about 50% of the tumors (Figure 3c ), indicating clearly that LOH on chromosome 16 is not driven by p63, but by an alternative tumor suppressor gene located near p63 on this chromosome.
In order to determine whether the remaining wildtype p63/p73 alleles were inactivated by methylation leading to loss of expression, we carried out RT-PCR analysis to detect expression of p63/p73 in tumors. In all tumors studied p73 was expressed, and loss of p63 expression was seen in that subset of tumors with deletions of the wild-type allele, in agreement with the microsatellite analysis (Figure 4) . No mutations were found in p63 or in p73 by sequence analysis of the (Mills et al., 1999) or p73 heterozygous mice were crossed with wild-type mice to generate wild-type and heterozygous mice. All mice received a single dose of 4 Gy gamma radiation at age of 5 weeks and monitored daily until moribund, then killed and autopsied. There were no statistically significant differences between p63 þ /À (or p73 þ /À) and wildtype mice by Kaplan-Meier analysis using the SPSS software 
heterozygous mice were crossed with p53À/À mice to generate p53 single and p53/p63 or p53/p73 double heterozygous mice. All mice were treated as described in Figure 1 legend. There were no statistically significant differences between p53 þ /À and p53 þ / Àp63 þ /À (or p53 þ /Àp73 þ /À) mice by Kaplan-Meier analysis using the SPSS software p53-mediated lymphoma suppressor activity in vivo J Perez-Losada et al complete coding regions (data not shown). Although our primers cannot distinguish between active and dominant negative isoforms, and we cannot detect differences in the relative expression levels between them, the facts that: (1) the remaining allele was not deleted, and more important, (2) there were no significant differences in survival rates between p53 single and double heterozygous mice, suggest that the relative expression levels between these two classes of proteins encoded by the remaining allele do not have any influence in lymphoma development. Our data indicate that there is no obvious collaboration between p53 and its homologues, p63 and p73, in suppression of radiation-induced lymphoma development. It has been proposed that p63 and p73 are overexpressed in human cancers compared with normal tissues (Zaika et al., 1999; suggesting the possibility that these proteins could function more as oncogenes than as tumor suppressors . However, interpretation of these results is complicated by the presence of different isoforms, some of which lack the transactivation domain and/or have dominant negative activity (Zaika et al., 1999; Crook et al., 2000; Hibi et al., 2000; Park et al., 2000; . Interestingly, high levels of truncated p63 isoforms have been described mainly in squamous cell carcinomas (Crook et al., 2000; Hibi et al., 2000; Park et al., 2000) a type of tumor that is very uncommon in p53 knockout mice. On the other hand, it has been proposed that p53 gain of function mutants can exert a dominant negative effect on p63 and p73, leading to epithelial tumors (Lang et al., 2004; Olive et al., 2004) .
Although our results demonstrate that p63/p73 do not contribute to p53 suppressor activity during development of radiation-induced lymphomas, some p53 mutants may be able to interfere with a putative tumor suppressor function for p63/p73 in other tissue types. Therefore, our data on lymphoma development do not discount the possible roles of p63 and p73 in the context 
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p53+/-p53+/-p63+/-p53+/-p73+/- (a) LOH analysis at the p53 locus by PCR using D11Mit marker. p53 remaining wild-type allele was deleted in 100% of the tumors. (b) LOH analysis at the p73 locus by PCR using D4Mit marker. (c) LOH analysis at the p63 locus by PCR using D16Mit marker. p63 locus was deleted in 70% of the cases, in half of them it was the 129sv knockout allele (tumors 11, 14, 15 and 19) , indicating that p63 is not the driving force in chromosome 16 deletion. PCR primer pairs for markers were purchased from Qiagen Operon (www.operon.com). PCR reactions were set up in a total volume of 20 ml, containing 2 ml of 10 Â PCR buffer (Bioline), 1.6 ml 0f 2.5 mM dNTPs (Pharmacia Biosystem Ltd.), 1 ml (6.6 mM) of each primer, 0.6 ml of 50 mM MgCl 2 (Bioline), 11.7 ml dH 2 O, 0.1 ml Taq polymerase (Bioline) and 2 ml (40 ng ml) tumor or normal tissue DNA. Amplifications were initially denatured at 941C for 3 min, followed by 35 cycles at 941C for 30 s, 551C or 521C for 30 s and 721C for 30 s, and then a final incubation at 721C for 5 min. The PCR products were then mixed with loading buffer and electrophoresed in 4% (3% NuSieve/1% agarose) agarose gel with 0.5 mg/ml ethidium-bromide, photographed and saved in image file for analysis of density of bands Figure 4 cDNA expression of the remaining p63/p73 alleles. p63 is not expressed in those tumors where the locus was found deleted (numbers 13, 16 and 20) . Total RNA was extracted from tumor tissue samples with the TRIzol reagent (Invitrogen Life Technologies). Reverse transcription-PCR were performed used Thermoscriptt RT-PCR system (GIBCO-BRL) and performed according to manufacturer's instruction. Expression of the p63 or p73 gene was performed by PCR amplification of cDNA from thymic lymphomas by using the following primers: p63F: 5 0 -CCTTATGAGCCACCACAGGT-3 0 ; p63R: 5 0 -TGCATCGAGGTCTGTTTCTG-3 0 .p73F: 5 0 -CATCCGTGTAGAAGGCAACA-3 0 ;p73R: 5 0 -CTCGCACGTGCATGTAGAAC-3 0 .These primers can amplify both active and dominant negative isoforms p53-mediated lymphoma suppressor activity in vivo J Perez-Losada et al
